Compare NVR & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVR | TEVA |
|---|---|---|
| Founded | 1980 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5B | 30.2B |
| IPO Year | N/A | N/A |
| Metric | NVR | TEVA |
|---|---|---|
| Price | $7,508.92 | $28.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $8,366.67 | $27.00 |
| AVG Volume (30 Days) | 20.7K | ★ 11.4M |
| Earning Date | 10-22-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 456.53 | 0.62 |
| Revenue | $10,582,633,000.00 | ★ $16,776,000,000.00 |
| Revenue This Year | N/A | $4.74 |
| Revenue Next Year | N/A | $0.48 |
| P/E Ratio | ★ $16.51 | $46.12 |
| Revenue Growth | ★ 2.93 | 0.02 |
| 52 Week Low | $6,562.85 | $12.47 |
| 52 Week High | $9,143.28 | $28.68 |
| Indicator | NVR | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 80.93 |
| Support Level | $7,450.00 | $24.01 |
| Resistance Level | $7,746.79 | $26.96 |
| Average True Range (ATR) | 142.52 | 0.68 |
| MACD | 46.78 | 0.19 |
| Stochastic Oscillator | 69.77 | 94.65 |
NVR Inc is a United States-based homebuilding company. It builds single-family detached homes, townhomes, and condominium buildings under three brands, Ryan Homes, NVHomes, and Heartland Homes. The company through its subsidiary also operates a mortgage banking and title services business. The homebuilding segment includes four geographic areas of the Mid-Atlantic, North East, Mid-East, and South East.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.